Stimulus Hopes Rise...
Health Care: Drugs
Abbott Laboratories (ABT: NYSE)
$60.22 -0.30 | -0.50%
06/04/12 - 04:02 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 60.52 |
| 52 Week High | 63.20 |
| 52 Week Low | 46.29 |
| Avg. Daily Vol. (Mil) | 7.34 |
| Beta (3 year) | 0.38 |
| Share Related Items | |
| Mkt Cap (Mil) | 95,221.65 |
| Shares Out (Mil) | 1,573.39 |
| Float (Mil) | 1,521.34 |
| Dividend Information | |
| Yield % | 3.40 |
| Annual Dividend | 2.04 |
| Payout Ratio | 59.00 |
| Financial Strength | |
| Quick Ratio | 1.00 |
| Current Ratio | 1.50 |
| LT Debt/ Equity | 0.47 |
| Total Debt / Equity | 0.65 |
| Valuation Ratios | |
| Price Earnings | 18.70 |
| Price/Sales | 2.42 |
| Price/Book | 3.74 |
| Price/Cash Flow | 11.70 |
| Per Share Data | |
| Earnings | 3.23 |
| Sales | 24.96 |
| Book Value | 16.18 |
| Cash Flow | 5.18 |
| Business Summary | |
|---|---|
| Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. | |
| General Information | |
| 100 Abbott Park Road
Abbott Park, IL 60064-6400 |
|
| www.abbott.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 91000 | |
| CEO: Miles D. White | |
| Short Interest | |
| Current Month (Mil) | 23.44 |
| Previous Month (Mil) | 23.36 |
| Short Interest Ratio (Days) | 3.20 |
| Management Effectiveness | |
| Return on Equity | 20.10 |
| Return on Assets | 8.20 |
| Return on Investments | 13.70 |
| Profitability | |
| Gross Margin | 68.50 |
| EBIT Margin | 15.70 |
| Profit Margin | 13.00 |
Portfolios with ABT
- Portfolio NameUser Type
- ContributorRocket Stocks for the Week ...
- Contributor10 Best-Performing 'Dividen...
- Contributor3 Upcoming Spinoffs That Co...
- UserBen's Growth Dividend Stocks
- Userlj's Portfolio
- UserPerpetual growers
- UserEyeon
- UserStock
- Userdiz
- ContributorHighest-Yielding Drug Stocks
Latest ABT Headlines from TheStreet
- 5 Rocket Stocks to Buy in June 06.04.12 | 11:06 am
- 3 Stocks I Saw on TV, June 4
06.04.12 | 08:06 am - Cramer's 'Mad Money' Recap: Europe's Problems a Global Problem 06.01.12 | 07:06 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Loser 06.01.12 | 05:06 pm
- Cramer's 'Mad Money' Recap: Avoid These High-Drama Stocks! 05.30.12 | 08:05 pm
- Cramer on Retirement: Individual Stocks Are Right for Your 401(k) 05.29.12 | 06:05 am
- Abbott Laboratories (ABT): Today's Featured Drugs Loser 05.23.12 | 05:05 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Winner 05.16.12 | 04:05 pm
- Abbott Helps Big Pharma Look Even Worse 05.16.12 | 01:05 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Loser 05.09.12 | 05:05 pm
Press Releases for ABT
- Abbott Again Recognized As One Of The 'Best Places To Work In Industry' By The Scientist Magazine - PR Newswire 06.01.12 | 09:06 am
- Absolute Software Partners With InComm To Sell LoJack For Laptops Through Major U.S. Retailers - PR Newswire 05.31.12 | 07:05 am
- Abbott To Present At Goldman Sachs 33rd Annual Global Healthcare Conference - PR Newswire 05.29.12 | 09:05 am
- Abbott To Present Wide Range Of Investigational Efficacy, Safety And Health Outcomes Data On HUMIRA® (Adalimumab) At The Annual Meeting Of The European League Against Rheumatism - PR Newswire 05.29.12 | 01:05 am
- Absolute Software Awarded Lenovo Top Supplier Award - PR Newswire 05.16.12 | 07:05 am
- Absolute Software Releases Turnkey BYOD Support For All Apple, Android And Windows Mobile Devices, Including Laptops - PR Newswire 05.15.12 | 08:05 am
- Abbott's XIENCE PRIME⢠And XIENCE V® Drug Eluting Stents Receive Indication In Europe For Minimum Three-Month Duration Of Dual Anti-Platelet Therapy - PR Newswire 05.15.12 | 08:05 am
- Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System With Insulin Calculator Now Available In Canada - PR Newswire 05.10.12 | 01:05 am
- Absolute Software Reaches Favourable Settlement Agreement In Precedent Setting Anti-Theft Patent Infringement Case - PR Newswire 05.08.12 | 06:05 pm
- Grant & Eisenhofer Represents Lead Whistleblower In Historic $1.6 Billion Settlement With Abbott Laboratories Over Off-Label Marketing Of Antiepileptic Medication Depakote - PR Newswire 05.07.12 | 02:05 pm
Partner Headlines for ABT
- Healthcare Business Recap: Dendreon BOMBS, Cancer Cures Galore - Wall St. Cheat Sheet 06.04.12 | 06:06 am
- Watchdog: Cramer Tells Investors Buy These 5 Stocks Now! - Wall St. Cheat Sheet 05.31.12 | 09:05 am
- 5 Strong Companies That Increased Yields By More Than 10% Over The Past 3 Years - Seeking Alpha 05.30.12 | 09:05 am
- Mason Hawkins' Southeastern Discusses Abbott Labs - GuruFocus 05.23.12 | 04:05 pm
- Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases - Zacks 05.23.12 | 09:05 am
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- Auxilium-Glaxo to Drive Testim Sales - Analyst Blog - Zacks 05.22.12 | 10:05 am
- Big-Cap Leaders Bland, But Their Charts Holding Up - Investor's Business Daily 05.21.12 | 07:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
